Literature DB >> 3082443

Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A.

A Meyrier, P Simon, G Perret, M C Condamin-Meyrier.   

Abstract

Nephrotic syndrome in minimal change lipoid nephrosis and focal segmental glomerulosclerosis may be due to alteration of glomerular anionic sites by a lymphokine. Six adults with nephrotic syndrome who were resistant to treatment with corticosteroids and immunosuppressants were treated with cyclosporin A. In three patients with minimal change lipoid nephrosis who had been nephrotic for 3.5 to 23 years proteinuria resolved within 12 to 42 days. Subsequently, these patients became dependent on cyclosporin A. In three patients with focal segmental glomerulosclerosis who had been nephrotic for four to six years mean (SD) 24 hour urinary protein decreased from 14.7 (8.4) g to 3.6 (0.6) g within 20 to 25 days, serum albumin concentration rose, and oedema subsided. One patient died of myocardial infarction when still in partial remission after 11 weeks' treatment. Two patients remained proteinuric despite continuing treatment with cyclosporin A, but control of sodium balance was easy and serum albumin concentrations remained higher than without cyclosporin A. In all patients renal function improved during treatment. These preliminary results show that cyclosporin A may be effective in the treatment of patients with nephrotic syndrome that resists every other form of treatment and especially in the treatment of those with minimal change lipoid nephrosis. The results are in keeping with a T lymphocyte mediated mechanism of minimal change lipoid nephrosis and focal segmental glomerulosclerosis, but they also suggest that minimal change lipoid nephrosis and focal segmental glomerulosclerosis are separate entities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082443      PMCID: PMC1339719          DOI: 10.1136/bmj.292.6523.789

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  19 in total

Review 1.  The pathogenesis of minimal change nephropathy.

Authors:  N P Mallick
Journal:  Clin Nephrol       Date:  1977-03       Impact factor: 0.975

2.  Recurrence of idiopathic nephrotic syndrome after renal transplantation.

Authors:  J R Hoyer; R L Vernier; J S Najarian; L Raij; R L Simmons; A F Michael
Journal:  Lancet       Date:  1972-08-19       Impact factor: 79.321

3.  Lymphocyte subpopulations in minimal change nephrotic syndrome.

Authors:  H O Kerpen; J G Bhat; R Kantor; B Gauthier; K R Rai; R G Schacht; D S Baldwin
Journal:  Clin Immunol Immunopathol       Date:  1979-09

Review 4.  Cellular immunity in glomerulonephritis.

Authors:  H M Fillit; J B Zabriskie
Journal:  Am J Pathol       Date:  1982-11       Impact factor: 4.307

5.  Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF.

Authors:  A D Hess; P J Tutschka; G W Santos
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

6.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function.

Authors:  R J Shalhoub
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

7.  A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome.

Authors:  G Lagrue; S Xheneumont; A Branellec; G Hirbec; B Weil
Journal:  Biomedicine       Date:  1975-02-10

8.  Focal segmental glomerulosclerosis with rapid decline in renal function ("malignant FSGS").

Authors:  C B Brown; J S Cameron; D R Turner; C Chantler; C S Ogg; D G Williams; M Bewick
Journal:  Clin Nephrol       Date:  1978-08       Impact factor: 0.975

9.  Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome.

Authors:  I Ichikawa; H G Rennke; J R Hoyer; K F Badr; N Schor; J L Troy; C P Lechene; B M Brenner
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  20 in total

1.  [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome].

Authors:  Zhi-Hui Li; Zhi Lin; Cui-Rong Duan; Tian-Hui Wu; Mai Xun; Yi Zhang; Liang Zhang; Yun-Feng Ding; Yan Yin
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-02

Review 2.  Treatment with cyclosporin of patients with idiopathic nephrotic syndrome.

Authors:  A Meyrier
Journal:  Springer Semin Immunopathol       Date:  1987

3.  Serum interleukin-2 levels in a patient with focal segmental glomerulosclerosis. Relationship to clinical course and cyclosporin A therapy.

Authors:  S C Jordan; U Querfeld; M Toyoda; J Prehn
Journal:  Pediatr Nephrol       Date:  1990-03       Impact factor: 3.714

Review 4.  The treatment of immune glomerular disease.

Authors:  D G Williams
Journal:  Springer Semin Immunopathol       Date:  1987

5.  Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience.

Authors:  M P Delaney; D C Dukes; M E Edmunds
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

Review 6.  Immunosuppressive therapy in the nephrotic syndrome in children.

Authors:  R S Trompeter
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

8.  Effect of cyclosporine A on circulating immune complexes in IgA nephropathy.

Authors:  K N Lai; C W Lam; I K Cheng; J S Tam; F M Lai
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

9.  Cyclosporin A treatment in children with minimal change nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  J Brodehl; M Brandis; U Helmchen; P F Hoyer; R Burghard; J H Ehrich; R B Zimmerhackl; W Klein; K Wonigeit
Journal:  Klin Wochenschr       Date:  1988-11-15

10.  Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats.

Authors:  Beom Seok Kim; Hyeong Cheon Park; Shin Wook Kang; Kyu Hun Choi; Sung Kyu Ha; Dae Suk Han; Ho Yung Lee
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.